NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

到2029年全球哮喘药物预测和市场分析

Asthma - Global Drug Forecast and Market Analysis to 2029

出版商 GlobalData 商品编码 979397
出版日期 内容资讯 英文 123 Pages
订单完成后即时交付
价格
到2029年全球哮喘药物预测和市场分析 Asthma - Global Drug Forecast and Market Analysis to 2029
出版日期: 2020年12月31日内容资讯: 英文 123 Pages
简介

哮喘是一种常见的慢性肺部疾病,最常见于儿童期,可发生于任何年龄。它的特征是慢性炎症,随后气道变窄,阻止空气通过肺部。哮喘可以是持续性或间歇性的,严重程度可能有所不同。有一种逐步治疗哮喘的方法,随著疾病严重程度的增加,治疗水平也随之提高。由于哮喘是高度异质性疾病,因此这些靶向疗法有多种不同的类型,其中一些目前处于后期开发阶段。三重吸入疗法预计将在预计的时间内增加患者的份额,以增加对中度至重度哮喘患者的适应性。

本报告涵盖了非处方药和后期管道哮喘治疗的市场预测。我们还按严重程度对哮喘患者进行分类。以2019年为基准年,我们汇总了2020年至2029年的预测。

目录

第1章目录

  • 表列表
  • 图列表

第2章哮喘:执行摘要

  • 在预测期内,哮喘市场将保持保守增长
  • GlaxoSmith Kline和Astra Zeneca牵头
  • 未满足的重症哮喘患者需要围绕诊断和治疗选择
  • 后期开发计划可满足个性化和便捷药品的需求
  • 医生的觀点

第3章简介

  • 促进因素
  • 相关报告
  • 未来相关报告

第4章疾病概述

  • 病因与病理生理
    • 病因
    • 病理生理学
  • 疾病严重程度分类

第5章流行病学

  • 疾病背景
  • 危险因素和合并症
  • 全球和历史趋势
  • 预测调查方法
    • 来源
    • 预测的前提条件和方法
  • 哮喘的流行病学预测(2019-2029)
    • 终身诊断哮喘患病率
    • 按年龄患病率对哮喘的终生诊断
    • 性别一生对哮喘的诊断率
    • 严重程度哮喘终生诊断率
  • 讨论
    • 瞭解流行病学预测
    • 分析极限
    • 分析优势

第6章疾病管理

  • 诊断和治疗概述
    • 诊断
    • 治疗指南和临床实践
  • 美国
  • 欧盟5个国家
  • 日本

第7章竞争力评估

  • 概述

第8章需求和机会评估

  • 概述
  • 准确的诊断
  • 严重哮喘的个性化治疗
  • 改善患者兼容性
  • 减少治疗费用

第9章管道评估

  • 概述
  • 临床开发中有希望的药物
    • 胸间质磷脂生成素抑制剂
    • CRTH2拮抗剂
    • 吸入皮质类固醇/长效Beta激动剂/长效毒蕈鹼拮抗剂
  • 其他正在开发的药物

第10章,当前和将来的玩家

  • 概述
  • 企业战略趋势
  • AstraZeneca
  • Novartis
  • Roche/Genentech
  • GlaxoSmithKline
  • Teva
  • Boehringer Ingelheim
  • Merck
  • Chiesi
  • Regeneron/Sanofi
  • AB Science SA

第11章市场前景

  • 世界市场
    • 预测
    • 驱动因素和壁垒-世界问题
  • 美国
    • 预测
    • 重要事件
    • 增长因素和障碍
  • 欧盟5个国家
    • 预测
    • 重要事件
    • 增长因素和障碍
  • 日本
    • 预测
    • 重要事件
    • 增长因素和障碍

第12章附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC208PIDR

Asthma - Global Drug Forecast and Market Analysis to 2029

Asthma is a common chronic lung disease that most often develops during childhood, although it can occur at any age. It is characterized by chronic inflammation and subsequent narrowing of the airways, which obstructs the passage of air through the lungs. Asthma can be persistent or intermittent, and also varies in severity. The treatment of asthma involves a step-wise approach, where the level of therapy increases as the disease severity increases. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies, of which some are currently in the late-stage pipeline. Triple inhaled therapies are forecasted to grow in patient share over the forecasted period to increase compliance rates amongst moderate to severe asthma patients.

This model covers the market forecast for the marketed and late-stage pipeline asthma therapeutics. The model segments asthma patients by severity. The base year of this model is 2019, and the forecast period is 2020-2029.

Key Highlights

  • The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the asthma market include high genericization of historical drug classes.
  • Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.
  • The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of asthma in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for asthma? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the asthma market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

  • Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global asthma therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Asthma: Executive Summary

  • 2.1 Asthma Market to Experience Conservative Growth Over the Forecast Period
  • 2.2 GlaxoSmithKline and AstraZeneca Lead the Way
  • 2.3 Unmet Needs Remain Surrounding Asthma Diagnosis and Treatment Options for Severe Patients
  • 2.4 Late-Stage Pipeline Addresses Needs for Personalized and Convenient Medications
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification of Disease Severity

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for Asthma (2019-2029)
    • 5.5.1 Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
    • 6.1.1 Diagnosis
    • 6.1.2 Treatment Guidelines and Clinical Practice
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview

8 Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Accurate Diagnosis
  • 8.3 Personalized Therapies for Severe Asthma
  • 8.4 Increased Patient Compliance
  • 8.5 Lower Cost of Therapy

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 Thymic Stromal Lymphopoietin Inhibitors
    • 9.2.2 CRTH2 Antagonist
    • 9.2.3 Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist
  • 9.3 Other Drugs in Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 AstraZeneca
  • 10.4 Novartis
  • 10.5 Roche/Genentech
  • 10.6 GlaxoSmithKline
  • 10.7 Teva
  • 10.8 Boehringer Ingelheim
  • 10.9 Merck
  • 10.10 Chiesi
  • 10.11 Regeneron/Sanofi
  • 10.12 AB Science SA

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers

12 Appendix

List of Tables

List of Tables

  • Table 1: Asthma: Key Metrics in the 7MM
  • Table 2: Classification of Asthma by Severity
  • Table 3: Risk Factors and Comorbidities for Asthma
  • Table 4: Treatment Guidelines for Asthma across the 7MM
  • Table 5: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 6: Country Profile - US
  • Table 7: Country Profile - 5EU
  • Table 8: Country Profile - Japan
  • Table 9: Leading Treatments for Asthma, 2020
  • Table 10: AstraZeneca's Asthma Portfolio Assessment, 2020
  • Table 11: Novartis' Asthma Portfolio Assessment, 2020
  • Table 12: Roche/Genentech Asthma Portfolio Assessment, 2020
  • Table 13: GlaxoSmithKline's Asthma Portfolio Assessment, 2020
  • Table 14: Teva's Asthma Portfolio Assessment, 2020
  • Table 15: Boehringer Ingelheim's Asthma Portfolio Assessment, 2020
  • Table 16: Merck's Asthma Portfolio Assessment, 2020
  • Table 17: Chiesi's COPD Portfolio Assessment, 2019
  • Table 18: Regeneron/Sanofi's Asthma Portfolio Assessment, 2020
  • Table 19: AB Science Asthma Portfolio Assessment, 2020
  • Table 20: Asthma Market - Global Drivers and Barriers, 2019-2029
  • Table 21: Key Events Impacting Sales for Asthma in the US, 2019-2029
  • Table 22: Asthma Market - Drivers and Barriers in the US, 2019-2029
  • Table 23: Key Events Impacting Sales for Asthma in the 5EU, 2019-2029
  • Table 24: Asthma Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 25: Key Events Impacting Sales for Asthma in Japan, 2019-2029
  • Table 26: Asthma Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 27: Key Historical and Projected Launch Dates for Asthma
  • Table 28: Key Historical and Projected Patent Expiry Dates for Asthma
  • Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Asthma in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for Asthma, 2020